Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. [electronic resource]
Producer: 20190521Description: 3288-3300 p. digitalISSN:- 1476-5594
- Aniline Compounds -- pharmacology
- Antineoplastic Agents -- pharmacology
- Bridged Bicyclo Compounds, Heterocyclic -- pharmacology
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Drug Resistance, Neoplasm -- genetics
- Humans
- Oncogene Proteins, Fusion -- genetics
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Proto-Oncogene Proteins c-bcl-2 -- genetics
- Receptor Tyrosine Kinase-like Orphan Receptors -- genetics
- Sulfonamides -- pharmacology
- Survival Rate
- Translocation, Genetic -- drug effects
- Up-Regulation -- drug effects
- Wnt Signaling Pathway -- drug effects
- Wnt-5a Protein -- genetics
- rhoA GTP-Binding Protein -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.